End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.34 CNY | +3.41% | +1.68% | -15.68% |
Apr. 26 | Aier Eye Hospital Group Co., Ltd. Announces Profit Distribution Proposal for 2023 | CI |
Apr. 26 | Nomura Adjusts Aier Eye Hospital's Price Target to 15.35 Yuan From 22.14 Yuan, Keeps at Buy | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With an expected P/E ratio at 31.28 and 24.31 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 5.02 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.68% | 17.21B | B+ | ||
+4.50% | 12.54B | B | ||
+4.48% | 11.71B | B+ | ||
+3.44% | 10.43B | B+ | ||
+26.66% | 8.51B | B | ||
-1.92% | 7.74B | A- | ||
+20.39% | 7.18B | D | ||
+3.42% | 6.55B | B- | ||
+46.01% | 4.5B | - | ||
-6.40% | 4.19B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300015 Stock
- Ratings Aier Eye Hospital Group Co., Ltd.